Citigroup Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lewis has maintained a Neutral rating on Intellia Therapeutics (NASDAQ:NTLA) and lowered the price target from $44 to $40.
August 04, 2023 | 3:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Citigroup has maintained a Neutral rating on Intellia Therapeutics and lowered the price target from $44 to $40.
The lowering of the price target by Citigroup indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100